Skip to main content

Advertisement

Log in

Experience with hormone receptors in renal cancer

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

The hormone receptor concentrations in tumour tissues from 20 renal carcinoma patients were determined before postoperative medroxyprogesterone acetate (MPA) therapy was started. Except for glucocorticoid receptors, the concentrations were either not measureable or were extremely low. The question is whether MPA therapy, solely on the strength of its character as a general roborant, is still useful in the treatment of renal tumours, even when it fails to exercise primary influence because of the absence of suitable receptors. None of the 20 patients was treated with MPA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bloom, H. J. G.: Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer.Br. J. Cancer, 25, 250 (1971).

    PubMed  CAS  Google Scholar 

  2. Bojar, H.: Steroidrezeptoren. In: K.-G. von Boroviczény, R. Merten, U. P. Merten (eds): Qualitätssicherung im medizinischen Laboratorium. Springer Verlag, Berlin 1987, p. 458.

    Google Scholar 

  3. Bojar, H.: Hormone responsiveness of renal cancer.World J. Urol., 2, 98 (1984).

    Article  Google Scholar 

  4. Concolino, G., di Silvero, F., Marocchi, A., Bracci, U.: Renal cancer steroid receptors: biochemical basis for endocrine therapy.Eur. Urol., 5, 90 (1979).

    PubMed  CAS  Google Scholar 

  5. Concolino, G., Marocchi, A., Conti, D., Tenaglia, R., Di Silvero, F., Bracci, U.: Human renal cell carcinoma as a hormone-dependent tumor.Cancer Res., 38, 4340 (1978).

    PubMed  CAS  Google Scholar 

  6. Di Fronzo, G., Ronchi, E., Bertuzzi, A., Vezzoni, P., Pizzocaro, G.: Estrogen receptors in renal carcinoma.Eur. Urol., 6, 307 (1980).

    PubMed  Google Scholar 

  7. Kopper, L., Magyarossy, E., Nagy, P., Lapis, K., Számel, J., Eckhardt, S. Csata, S., Wabrosch, G., Répássy, D.: Renal cell carcinoma—xenotransplantation into immune suppressed mice.Oncology, 41, 1924 (1984).

    Google Scholar 

  8. Nakano, E., Yasaharu, T., Hideki, F., Minoru, M., Masao, O., Thoshihiko, K. Burizo, S., Minato, T., Takao, S.: Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy.J. Urol., 132, 240 (1984).

    PubMed  CAS  Google Scholar 

  9. Pearson, J., Friedmann, M. A., Hoffmann, P. G.: Hormone receptors in renal cell carcinoma. Their utility as predictors of response to endocrine therapy.Cancer Chemother. Pharmacol., 6, 151 (1981).

    Article  PubMed  CAS  Google Scholar 

  10. Orovan, W. L., Ryan, E. D.: Estrogen and progesterone binding sites in renal cell carcinoma.Urology, 34, 65 (1989).

    Article  PubMed  CAS  Google Scholar 

  11. Servadio, C.: Steroid receptors in renal cell carcinoma.J. Urol., 131, 227 (1984).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Romics, I., Rüssel, C. & Bach, D. Experience with hormone receptors in renal cancer. International Urology and Nephrology 22, 507–512 (1990). https://doi.org/10.1007/BF02549737

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02549737

Keywords

Navigation